The antisense promoter of human LINE-1 (L1) retroelements can direct transcription of adjacent unique genomic sequences generating chimeric RNAs, which can perturb transcription of neighbouring genes. As L1 elements constitute 17% of the human genome, chimeric transcription is potentially widespread, but the extent to which this occurs is largely unknown. Using a genome-wide screen we have isolated novel chimeric transcripts that are unique to breast cancer cell lines, primary tumours and colon cancer cells. Expression of the cancer-specific chimeric transcripts can be induced in non-malignant breast epithelial cells by the demethylating drug 5-azacytidine. These findings indicate that loss of L1 methylation in cancer cells is linked to the expression of L1-chimeric transcripts which may therefore constitute a useful set of markers of malignancy.
Introduction
LINE-1 (L1) retrotransposons are the most common autonomous elements in the human genome comprising 17% of the DNA [1] . Fulllength L1 elements consist of 5′ and 3′ untranslated regions (UTR) and two open reading frames that encode genes for retrotransposition (ORF-1 and ORF-2) (Fig. 1A) . The 5′UTR contains a bidirectional promoter: the sense promoter transcribes the two open reading frames and the antisense promoter (ASP) can direct transcription of the adjacent genomic DNA [2] . However, the majority of the estimated 500,000 copies of L1 elements present in the human genome are truncated, rearranged, or mutated and only 177 of the about 7000 extant fulllength elements are potentially retrotransposition-competent [3] .
L1 elements, even those lacking retrotransposition capacity, can influence the transcription of the unique sequences within a cell, contributing to the regulation and diversity of gene expression patterns. For example, intronic L1 elements can provide alternative splice and polyadenylation sites [4, 5] and influence transcript levels of the host gene [6, 7] . Furthermore, the L1 antisense promoter can transcribe regions of unique sequence leading to the production of chimeric transcripts found in a variety of cell types [2, 8] . The LINE-1 ASP (L1-ASP) can act as a tissue-specific promoter and, depending on the relative orientations of the L1 and the cellular genes, L1-ASP can drive sense or antisense transcription leading to alternative splice variants of several cellular genes or antisense RNAs containing regions of complementarity to exons of mRNAs [9] . Moreover, it has been recently reported that the majority of natural antisense transcripts initiate at L1 elements [10] and as antisense transcription can alter the local chromatin structure and lead to gene activation [11] [12] [13] , or silencing [14] [15] [16] , these transcripts have the potential to influence gene expression patterns; however, few studies have looked at this in detail.
Some reports implicate chimeric transcripts in cancer. For example, a cancer-specific L1-ASP-driven transcript was identified in oesophageal adenocarcinoma [17] . In addition, activation of an L1 in the first intron of the MET proto-oncogene leads to L1-ASP-driven transcription of a truncated isoform of this gene which is associated with increased risk of progression to blast crisis in chronic myeloid leukaemia patients and decreased levels of methylation at L1 elements [18] .
Hypomethylation at repetitive DNA is a general feature of cancer cells [19] . The molecular mechanisms underlying cancer-related loss of methylation are largely unknown [20] , but there is strong evidence indicating that hypomethylation plays an active role in cancer progression. In mouse models, loss of the maintenance DNA methyltransferse, Dnmt1, leads to hypomethylation, activation of retroelements, and susceptibility to tumours [21, 22] ; moreover, in some human cancers, there is a direct correlation between the severity of the disease and the decrease in methylation at the L1 promoter [23] . Indeed, loss of methylation and activation of transposable elements have been proposed as factors promoting malignancy progression [21, 22, 24] . One hypothesis suggests that L1 hypomethylation leads to an increase in retrotransposition and genomic instability, promoting cancer progression [25] [26] [27] , and that methylation of retroelements is an important mechanism to prevent retrotransposition in somatic cells [28, 29] . Despite this, evidence of augmented transposition in tumours is scant [20] and the effects that hypomethylation has on the transcriptional activation of L1 promoters leading to the genome-wide production of chimeric transcripts are not understood.
Here, we have developed a genome-wide RT-PCR based technique, L1 chimera display, to isolate novel L1-chimeric transcripts and compare the levels of expression of these in normal and cancer cell lines. Furthermore, we have used a tissue culture system to investigate the role of global hypomethylation in their regulation in cancer cells.
Results

Isolation of L1-chimeric transcripts (L1 chimera display)
L1 chimera display (LCD) was developed to amplify and display RNAs containing L1-ASP and unique sequences, hereafter referred to as L1-chimeric transcripts (LCT). This method is a modification of a technique used to amplify transcripts containing HERV K LTRs [30] and is schematically represented in Fig. 1B (see Materials and methods for details). Double-stranded cDNA is synthesised from total RNA (I). The cDNA is digested with a restriction enzyme which does not cut within the L1-ASP sequence and adapter linkers are ligated into the overhangs created (II). Nested PCR is performed using a primer within the L1-ASP (RB5PA2 or 20a) and a primer specific to the adapter region. The adapters are designed to allow suppression PCR and prevent the amplification of fragments that do not contain the L1-ASP sequence [31] . The PCR products can then be displayed by agarose gel electrophoresis or cloned into libraries.
A representative result of the LCD technique performed on total RNA from normal and breast cancer cells is shown in Fig. 1C , demonstrating an increase in the number of L1-chimeric transcripts in MCF-7 breast cancer cells compared to normal breast. Using this method, libraries of LCTs were generated from breast cancer cell lines MCF-7, HCC-1954, and normal breast RNA. Table 1 lists the details of eighteen LCTs cloned and sequenced by initial sampling of the libraries. Eight of the sequenced LCTs contain entirely repetitive sequences such as other LINE and LTR transposable elements. Furthermore, ten of the transcripts sequenced were novel, contained unique sequences, and could be mapped to specific genomic loci near or within coding genes (Table 1) . Schematic representation of the LCD technique. Shown are the 4 main stages of the technique: conversion of total RNA to double-stranded cDNA (I). The cDNA is digested with a restriction enzyme (in this case XbaI) that does not cut within L1-ASP, and complementary adapters are ligated onto the overhangs (II). These adapters have a high CG content and form panhandle structures which only permit the amplification of those containing a binding site for the L1-specific primer RB5PA2 with the adapter-specific primer 42c (III). Nested PCR is carried out using primers 20a (L1-specific, panel A) and 42d (IV), PCR products can be cloned into a library or visualised by electrophoresis. (C) Visualisation of LCD products from normal breast and the MCF-7 cancer cell line. Gel electrophoresis shows many LINE-1 chimeric transcripts in the cancer cell line than in normal breast.
A subset of L1-chimeric transcripts is breast cancer-specific Seven of the new L1-chimeric transcripts identified by LCD were validated by strand-specific RT-PCR in DNaseI-treated total RNA from two breast cancer cell lines and from two primary samples of normal breast tissue from a commercial source (one representative normal sample is shown in Fig. 2A ). LCT8 and 9 are present in normal breast and in cancer cell lines, LCT14, 15, and 17 are unique to MCF-7 cells and LCT13 and 18 are shared by both HCC-1954 and MCF-7 ( Fig. 2A) . These results are consistent with the display in Fig. 1C indicating that more L1-containing transcripts are present in cancer cell lines than normal controls. As L1 insertions can be polymorphic among human populations, the corresponding genomic DNA was analysed by PCR to determine if the lack of expression of individual LCTs was due to absence of the L1 element. Only the L1 element associated with LCT15 is polymorphic among the cell lines studied and not present in HCC-1954 (Fig. 2B) . Therefore, absence of LCT expression is more likely due to repression of transcription rather than to polymorphic L1 insertions.
Expression of the LCTs was analysed in total RNA isolated from primary tumours and matched adjacent normal breast tissue of five independent breast cancer patients (Fig. 2C) . Consistent with the results in Fig. 2A , LCT8 and 9 were found in both normal and tumour samples, whilst all of the cancer-specific LCTs (LCT13-18), with the exception of LCT14, are present or enhanced in one or more of the tumour samples (Fig. 2C ). It seems, therefore, that the differences observed between the cell lines and normal controls can distinguish a tumour from its matched control, strengthening the correlation between expression of the cancer-specific LCTs and a malignant phenotype.
L1-chimeric transcripts initiate at L1-ASP
The LCD technique isolates L1-ASP containing transcripts but is unable to distinguish between LCTs that originate at L1-ASP and those that are part of larger read-through transcripts. Using a retrotransposition-competent transgenic construct L1-ASP initiation sites have been mapped in the regions of + 378 to +431 and +480 to +497 [32] . Therefore, LCTs driven by L1-ASP should not contain L1-ORF-1 sequences and no amplification should be observed by RT-PCR using a primer specific to the unique region and primers complementary to L1-ORF-1 (Fig. 3A) . Strand-specific RT-PCR reveals that LCT8, 9, and 15 may be part of read-through transcripts initiating from upstream promoters (Fig. 3B ). In contrast, no product was obtained by amplification with ORF-1 primers 18e and 18f and the unique primer in LCT13, 14, 17, and 18 ( Fig. 3B and data not shown), suggesting that they may originate from L1-ASP. To confirm this, 5′RACE was performed on LCT13 and LCT14 and two products were obtained for each LCT which were cloned, sequenced, and mapped to the L1-ASP at the respective genomic locations. This analysis revealed that LCT13 and LCT14 indeed initiate at L1-ASP, with transcription start sites for LCT13_a and _b found at +160 and +197, respectively, for LCT14_a at +495 and for LCT14_b at +180 (Fig. 3C ). These findings suggest that initiation of transcription at endogenous L1-ASP sequences is more variable than what observed in the transgenic construct [32] , accounting for the initiation site mapping further downstream than those observed in the retrotransposition-competent transgene, and demonstrate that some of the cancer-specific LCTs that become active during tumourigenesis are derived from L1-ASP.
L1-chimeric transcripts are also present in colon cancer
To assess whether LCT expression is a more general trait of cancer, strand-specific RT-PCR analysis and genotyping was extended to total RNA from normal colon and three colon cancer cell lines: HCT-116 RT-PCR analysis of seven LCTs using the LCT-specific primers in combination with a primer within L1 ORF-1 (18f). Note that LCT8, LCT9, and LCT15 have read-through transcription, whereas LCT13, LCT14, LCT17, and LCT18 are likely to originate at the L1 ASP. (C) Mapping to the L1 5′UTR of the sequences of the clones obtained by 5′RACE on LCT13 (LCT13_a and LCT13_b) and LCT14 (LCT14_a and LCT14_b) confirms that these LCTs initiate at L1-ASP.
isolated from an invasive colorectal carcinoma, and a pair of isogenic cell lines established from the same individual at two different stages of malignancy; SW480 derived from colorectal adenocarcinoma and SW620 derived from a lymph node metastasis. PCR genotyping confirms the presence of the seven L1 elements in the three cell lines, except for the L1HS associated with LCT15 which is absent in HCT-116 and SW480 and SW620, but present in the normal colon samples tested (Fig. 4A) .
Strand-specific RT-PCR analysis of total RNA from the colon cancer cell lines reveals that LCT18 is expressed in normal colon, suggesting a different pattern of expression to normal breast, whilst expression of the other LCTs is restricted to the cancer cell lines. Hence, similar to observations in breast cancer cells, the presence of the L1 insertion is not sufficient for LCT expression and there is cancer-specific LCT expression. It is noteworthy that the L1-driven transcripts LCT13, 14, and 17 are found in the invasive SW620 and not in SW480 (Fig. 4B) , suggesting that their expression is associated with progression to an invasive phenotype.
Increased expression of L1-ASP containing transcripts correlates with DNA hypomethylation
Having shown cancer-specific expression of LCTs in both breast and colon cancer cells, and that their absence in normal cells is not merely due to polymorphic L1 insertions, we wished to address the molecular mechanism responsible for this activation. As L1 hypomethylation has been observed in a wide range of cancers [33, 34] , and has been proposed to activate an LCT at the MET gene [18] , we examined the correlation between global hypomethylation and expression of the L1-ASP-driven LCTs identified in this study (LCT13, 14, 17, and 18).
Levels of DNA methylation at L1 elements in breast cancer cell lines were compared to those of normal breast samples by methylationsensitive Southern blotting using the enzymes MspI, which is insensitive to CpG methylation (Fig. 5A, odd numbered lanes) , and its methylation-sensitive isoschizomer HpaII (Fig. 5A, even numbered  lanes) . A DNA probe spanning the L1 5′UTR (Fig. 1A) reveals that DNA from the breast cancer cell lines is more readily cleaved by the methylation-sensitive HpaII enzyme than a normal breast DNA control, indicating that in these cell lines the L1 promoter is hypomethylated (Fig. 5A) . Complete digestion was confirmed by hybridisation with a mitochondrial DNA probe [35] (data not shown). These data indicate that activation of L1-driven transcripts in breast cancer cells correlates to loss of methylation at the L1 promoter.
To determine if hypomethylation is sufficient to activate the cancer cell-specific LCTs, we treated the MCF-10A cell line, a spontaneously immortalized non-neoplastic human breast epithelial cell line with characteristic of normal breast [36] , with 5-azacytidine, an inhibitor of DNA methylation, to induce global loss of DNA methylation, thus mimicking cancer-related hypomethylation. Treated and untreated cells were analysed by Southern blotting as described above, showing that untreated MCF-10A cells have some degree of hypomethylation compared to normal breast tissue, but 5-azacytidine treatment leads to a further decrease (Fig. 5B) . The decreases in L1-ASP methylation in MCF-7 compared to normal breast (Fig. 5A ) and in 5-azacytidinetreated MCF-10A cells relative to untreated cells (Fig. 5B) are associated with an increase in transcripts containing the L1-ASP promoter, including read-through transcripts, as shown by semiquantitative RT-PCR (Fig. 5C ). Two-dimensional densitometry analysis was performed to determine the levels of L1-ASP containing transcripts relatively to two internal controls, the single-copy gene APRT and the multi-copy gene for the 18S ribosomal subunit (Figs. 5D and E). When comparing MCF-7 cells to normal breast, an increase in L1-ASP containing transcripts is evident when using both controls, with a value of 38% when normalised to APRT and 53% relatively to 18S (Fig. 5D) . Similarly, there is a 200% and 88% increase in L1-ASP transcripts in 5-azacytidine-treated MCF-10A cells compared to untreated cells relatively to APRT and 18S, respectively (Fig. 5E ). The differences in the relative enrichment observed using APRT and 18S as controls can be ascribed to differences in APRT expression levels relatively to 18S, an 11% increase in MCF-7 compared to normal breast and a 38% reduction in MCF-10A cells following 5-azacytidine treatment (Figs. 5D and E) . Taken together, these findings suggest an association between global hypomethylation and a rise in transcripts containing the L1-ASP.
Expression of cancer-specific LCTs can be induced in non-neoplastic breast cells by treatment with 5-azacytidine
Strand-specific RT-PCR was carried out to analyse the expression of the seven LCTs described above in 5-azacytidine-treated and untreated MCF-10A cells. Consistent with the initial observation that LCT8 and 9 are shared by normal and breast cancer lines, they could be detected in both treated and untreated cells, with an increase in the levels of LCT9 seen in 5-azacytidine-treated cells (Fig. 6A) . Two cancer-specific LCTs were activated in the 5-azacytidine-treated cells (LCT13 and LCT14) whilst two others remained silenced (LCT15 and 17) (Fig. 6A) . Loss of methylation at LCT14, as induced by 5-azacytidine treatment, was characterised in detail by bisulphite sequencing (Fig. 6B) , revealing that in mock-treated MCF-10A cells, the L1 5′UTR is substantially methylated. In comparison, 5-aza-treated MCF-10A cells have a subtle loss of DNA methylation at the L1-ASP of LCT14 paralleling the slight reduction observed by Southern blot analysis. It seems therefore that a decrease in the levels of DNA methylation can lead to activation of cancer-specific chimeric transcripts in non-neoplastic cells, but the extent to which individual L1s respond to this may vary.
Discussion
In this study, we devised a strategy to isolate chimeric transcripts containing L1-ASP and unique DNA sequences. Previously reported approaches for the identification of chimeric transcripts include the screening of oligo-d(T) primed cDNA libraries [2] or the use of bioinformatics and EST databases [8, 9] ; however, the LCD technique described here has no such bias allowing the identification of novel LCTs. We have isolated chimeric transcripts that may be representative of read-through transcription (LCT8, 9, and 15), as transcription was detected upstream of the corresponding L1-ASP, and further work is necessary to determine whether L1-ASP activation occurs at these elements. LCT13 and 14 initiate at L1-ASP as shown by 5′RACE, and LCT17 and 18 are likely to as no upstream transcription was detected.
As shown in Table 1 , the L1-ASP-driven transcripts originate not only at young L1 elements but also at older elements, which have accumulated mutations that prevent them from retrotransposing; nevertheless, these have maintained functional elements within their promoters that allow for transcriptional activation under permissive conditions. This is an important observation as none of the L1-ASPdriven LCTs (LCT13, 14, 17, and 18) contain the consensus sequence for active elements [3] and retrotransposition-competent elements are only a minority of the full-length L1 elements present in the genome [3, 34] . Future studies may reveal if the effects of transcriptional interference caused by activation of L1-chimeric transcripts are as extensive as the effects of retrotransposition or genomic rearrangements in cancer.
We have found that L1-driven LCTs are mainly specific to or increased in cancer cells compared with normal controls. This observation is pertinent for both breast and colon cancer cell lines and consistent with previous observations that L1-driven transcripts can be cancer-specific [17, 18] . Furthermore, matched normal and tumour breast samples follow this pattern, suggesting that these differences reflect a cancerous phenotype and not variation in the activity of L1 elements between individuals as has been found with reference to retrotransposition [37] .
Interestingly, the colon cancer-specific LCTs are not expressed in the SW480 colon adenocarcinoma cell line but are present in the invasive colon carcinoma cell line SW620 isolated from the same individual. Whilst changes in LCT expression may be due to differences in the tissue of origin of the cell lines; the SW480/ SW620 is an established model of tumour progression [38] and SW620 have retained the characteristics of colon epithelial cells [39, 40] . Therefore, there is an association between activation of some LCTs and cancer progression, a similar finding to that of the MET LCT [18] and it is tempting to speculate that the activation of LCTs plays a role in the advancement of cancer to metastasis or has the potential to act as a novel biomarker for disease progression.
In addition to demonstrating a correlation between hypomethylation of L1 elements and increased expression of chimeric transcripts, we have shown that the breast cancer-specific LCT13 and 14 are activated by 5-azacytidine treatment of non-malignant MCF-10A breast epithelial cells. LCT17 and 18 were not activated by hypomethylation implying that there are other mechanisms at play in regard to LCT activation or that the decrease in methylation obtained in MCF-10A was not sufficient for their expression. Nevertheless, these findings suggest that an increase of chimeric transcripts can be influenced by the levels of DNA methylation. As methylation levels at L1 elements can predict cancer status and outcome [23] , further work is necessary to establish if chimeric transcripts play a direct role in cancer pathogenesis.
It could be suggested that, as the intronic LCT18 is in a sense orientation with respect to the KIAA0146 gene in which it resides, there is potential for the L1-ASP to act as an alternative promoter producing a truncated version of this gene as has been previously observed at other genes [8, 9] . Moreover, LCTs such as LCT13, 14, and 17 are found in intergenic regions and are likely to represent noncoding transcripts. Evidence from other systems demonstrates that sense and antisense intergenic transcription can promote gene activation [11] [12] [13] , or silencing [14] [15] [16] , indicating that the ability of L1 to drive antisense transcripts may represent an additional way in which L1 contributes to alterations in gene expression patterns associated with disease phenotypes. However, further work is necessary to reveal if activation of L1-chimeric transcripts interferes with the transcriptional activity of the genes surrounding them.
Our findings indicate that in addition to the proposed role in genomic instability and chromosomal rearrangements, activation of L1 promoters at their original integration site can drive transcription through neighbouring regions of the genome contributing to changes in the cancer transcriptome. Future functional analysis of these transcripts is required to establish if they play a causative role in cancer progression. Furthermore, given the observation that L1 promoters are active early in development [41] , L1-driven chimeric transcripts may play a role in development and differentiation by shaping the transcriptional status of adjacent chromatin. The LCD technique described here, combined with high-throughput sequencing technologies, could provide a valuable tool for a systematic and exhaustive analysis of LCTs in normal development and differentiation, as well as in different cancer types.
Materials and methods
All the primers used in this study and their sequences are listed in Table 2 .
Normal and tumour tissue samples
All samples used in this study were purchased from AMS Biotechnology or Ambion.
Cell culture
MCF-7 and HCC-1954 (ATCC) cell lines were grown in RPMI 1640 medium (Gibco) with 10% foetal bovine serum (FBS). MCF-10A cells were grown in mammary epithelial growth medium (Lonza) with 100 ng/ml cholera toxin (Sigma). SW480 and SW620 cells were maintained in Leibovitz L-15 medium with 1% non-essential amino acids and 10% FBS. HCT-116 cells were grown in McCoy's 5A medium with 10% FBS. All cultures were supplemented with 100 μg/ml penicillin-streptomycin (Invitrogen) and incubated at 37°C with 5% CO 2 .
LINE-1 chimera display (LCD)
First-strand cDNA was synthesised using 5 μg total RNA with 250 ng random primers (Promega) and Superscript II according to the manufacturer's protocol (Invitrogen). Second-strand synthesis was then performed with 1× second-strand buffer (Invitrogen), 0.2 mM dNTPs, 10 U E. coli DNA ligase (NEB), 40 U E. coli DNA polymerase I (NEB), and 40 U RNase H (NEB) and incubated at 16°C for 2 hours and double-strand cDNA was purified by phenol/chloroform extraction followed by ethanol precipitation.
Approximately 1 μg of cDNA was digested with 60 U XbaI overnight. DNA was purified by phenol/chloroform extraction and ethanol precipitation. Linker 42ab was ligated to cDNA by T4 ligase (NEB) at a 20:1 ratio at 16°C overnight. Excess linkers were removed by Qiagen PCR Cleanup Kit and purified by phenol/extraction and ethanol precipitation. Linker 42ab was prepared by annealing All the primers were designed for this study with the exception of RB5PA2 as previously described [43] . equimolar (20 μM each) of 42a and 42b and incubation at 65°C for 10 min; the mix was cooled to 25°C by reducing the temperature by 1°C every minute. PCR amplification was carried out with 10 ng of adapter ligated cDNA with a primer specific to the outermost region of the adapter and a primer specific for L1-ASP, 42c, and RBPA2 (provided by R. Badge, University of Leicester), respectively. PCR conditions were as follows: initial denaturation at 95°C for 3 min, followed by 30 cycles of denaturation (1 min at 95°C), annealing (1 min at 59°C), and extension (3 min at 72°C). Nested PCR was performed using 42d, specific for the innermost part of the adapter, and 20a specific to LINE-1 ASP as above except annealing at 51°C. Products from nested PCR were directly cloned into pCR2.1 TA cloning vector according to the manufacturer's protocol (Invitrogen) and those positive for inserts were sequenced.
Strand-specific RT-PCR and 5′RACE
Total RNA was extracted from cells using TRI reagent (Sigma) as manufacturer's instructions. Prior to reverse transcription total RNA samples were DNaseI-treated as recommended by manufacturer (Invitrogen). Reverse transcription reactions were carried out using Superscript II (Invitrogen) as per the manufacturer's protocol and using 1 μg of DNaseI-treated total RNA as template. One microliter of first-strand cDNA was used as a template for PCR. PCR conditions were as follows: 1× Thermo Pol Taq buffer (NEB), 0.2 mM dNTPs (Amersham), 0.25 μM forward primer, 0.25 μM reverse primer, and 1.25 U Taq polymerase (NEB). PCRs were incubated at 95°C for 5 min followed by 30 cycles at 95°C for 1 min, appropriate annealing temperature (primer pair dependent) for 1 min and 72°C for 1 min with a final incubation at 72°C for 10 min. Gel images were acquired using a LAS-1000 gel documentation system (Fuji). Semi-quantitative PCRs were performed by increasing cycle numbers under conditions optimised for each primer pair (18, 22 , and 26 cycles for 18S; 26, 30, and 34 cycles for L1-ASP and APRT). For semi-quantitative analysis, two-dimensional densitometry evaluation was performed on four replicates of each experiment by region determination using the AIDA (Advanced Image Data Analyser) software (Raytest). The levels of each amplicon were calculated as the ratio of the mean of the amplicon values to the mean of the values of the chosen control, and standard error of the means was used to show the variations. The levels in MCF-7-and 5-aza-treated MCF-10A cells were expressed as a percentage of normal breast and untreated MCF-10A cells, respectively.
For the 5′RACE reactions, the first-strand cDNAs were synthesized in 50 μl reverse transcription (RT) reactions using 5 μg of total RNA from MCF-7 or SW620 cells, 10 pmol of primers 51c (LCT13), 52c (LCT14), and CT51 (APRT control), and Expand Reverse Transcriptase (Roche) in accordance with the manufacturer's directions. The cDNAs were tailed with poly(dC) using Terminal Transferase (NEB) according to the manufacturer's instructions. Three microliters of the tailed cDNA was then amplified for 30 cycles using primer 107 in LCT13 unique sequence or 109 in LCT14 unique sequence and the 5′RACE Anchor primer (Gibco BRL). A second round of PCR was performed on 1 μl of the first-round PCR products using primers 51b (LCT13) or 52b (LCT14) and the Abridged Universal Amplification Primer (AUAP, Gibco BRL). PCRs were performed using the Taq DNA Polymerase (NEB). 5′RACE products were cloned using the TA cloning kit (Invitrogen) according to the manufacturer's instructions. Positive clones were sequenced with M13F and M13R universal primers (Eurofins MWG Operon).
Treatment of cells with 5-azacytidine
MCF-10A cells were seeded at 1 × 10 6 with media conditions as described and grown for 24 hours. 5-Azacytidine (Sigma) prepared in dimethyl sulphoxide (DMSO, Sigma) was added to the medium at a final concentration of 1 μM. The media was changed and fresh 5-azacytidine was added every 24 hours for 72 hours. A flask with an equivalent amount of DMSO only was included as a mock-treated control.
Methyl-sensitive Southern blotting
Five micrograms of genomic DNA was digested with either MspI or its methyl-sensitive isoschizomer HpaII (NEB). Fragments were separated by agarose gel electrophoresis and DNA was transferred onto a nylon membrane (BioRad) by upward capillary action in 0.4 M NaOH. DNA was immobilised on the membrane by baking at 80°C. Blots were hybridised with a 32 P-radiolabelled probe specific to the 5′ UTR of human-specific L1 (a gift from R. Badge, University of Leicester) in a hybridisation solution (3× SSC, 10 mM EDTA, 0.2% PVP, 0.2% Ficoll, 0.2% BSA, 0.1% SDS, 0.04 mg/ml salmon sperm DNA and 0.02 mg/ml heparin, 9% dextran sulphate). The following day, blots were washed in 2× SSC/0.1% SDS twice for 5 min at room temperature and twice in 0.1× SSC/0.1× SDS for 15 min at 65°C. Membranes were exposed to autoradiograph film (Kodak) for imaging.
Bisulphite sequencing
One microgram of genomic DNA was digested with an appropriate restriction enzyme and bisulphite-treated as previously described [42] . Following treatment, nested PCR was performed using conditions as above. Products were then directly cloned into pCR2.1 TA cloning vector as per the manufacturer's protocol (Invitrogen) and those positive for inserts were sequenced.
